Genetic Risk Score Predicts Response to Triptans for Migraines Without Aura

Genetic risk scores that focus on 2 single-nucleotide polymorphisms associated with migraines without aura might help predict patient response to triptan treatment.

Source link

Related posts

Parkinson’s gene affects more people than previously thought


Silencing of immune activation with methotrexate in patients with COVID-19


Quanterix to convene leading industry researchers at Alzheimer’s Association International Conference 2019 following closing of UmanDiagnostics acquisition


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy